Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

BACKGROUND: Resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a major clinical challenge in advanced non-small cell lung cancer (NSCLC). Here, we report resistance mechanisms to abivertinib, a novel third-generation EGFR TKI, from a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi-Chen, Chen, Zhi-Hong, Zhang, Xu-Chao, Xu, Chong-Rui, Yan, Hong-Hong, Xie, Zhi, Chuai, Shao-Kun, Ye, Jun-Yi, Han-Zhang, Han, Zhang, Zhou, Bai, Xiao-Yan, Su, Jian, Gan, Bin, Yang, Jin-Ji, Li, Wen-Feng, Tang, Wei, Luo, Feng Roger, Xu, Xiao, Wu, Yi-Long, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558024/
https://www.ncbi.nlm.nih.gov/pubmed/31027916
http://dx.doi.org/10.1016/j.ebiom.2019.04.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558024/
https://www.ncbi.nlm.nih.gov/pubmed/31027916
http://dx.doi.org/10.1016/j.ebiom.2019.04.030

Ejemplares similares